Concat, Ltd.
Concord, CA, US· latest recorded location
Concat, Ltd. is named on 10 US grants and 1 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 10
- Published applications
- 1
- Inventors
- 7
- Granted in 2026 so far
- 0
- Most recent grant
- 19 Apr 2005
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 2 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 1 | 0 |
By publication year.
Technology areas
Share of 11 documents
- A61KMedicines and medical preparations11
- C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen7
- A61PTherapeutic uses of medicines6
- Y10TTechnical subjects covered by former us classification4
- A61QSpecific use of cosmetics or similar toiletry preparations3
- C07DHeterocyclic compounds3
- G01RMeasuring electric variables3
- Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests3
Recent patents
- Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements19 Apr 2005US 6,881,732 B2
- Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy and diagnosis22 Oct 2002US 6,469,162 B1
- Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury14 May 2002US 6,387,891 B2
- Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury24 Jul 2001US 6,264,966 B1
- Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis26 Dec 2000US 6,165,996 A
Most cited
By later US patents
- Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy49US 5,874,573 A1999
- MRI image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands18US 5,236,695 A1993
- MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms14US 5,409,689 A1995
- Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury9US 6,264,966 B12001
- Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury8US 6,387,891 B22002